Abstracts Archive - Page 787 of 1683 - ATC Abstracts

2018 American Transplant Congress
Glucocorticoid Receptor Polymorphism Affects Susceptibility of Dyslipidemia in Recipients One Year after Kidney Transplantation
K. Numakura,¹ H. Kagaya,² N. Komine,¹ R. Yamamoto,¹ N. Fujiyama,³ H. Tsuruta,¹ A. Maeno,¹ M. Saito,¹ S. Narita,⁴ T. Inoue,¹ T. Niioka,² M. Miura,² T. Habuchi,¹ S. Satoh.³
¹Urology, Akita University Graduate School of Medicine, Akita, Japan; ²Pharmacy, Akita University Hospital, Akita, Japan; ³Center for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan; ⁴Blood Purification, Akita University Hospital, Akita, Japan.
Purpose. Dyslipidemia (DL) is a critical comorbidity after renal transplantation and can arise cardiovascular diseases. The relationship between developing of DL and glucocorticoid receptor (NR3C1)…
2018 American Transplant Congress
Risk Factors for Graft Failure in Kidney Transplant Recipients with Polycystic Kidney Disease
G. Bhutani, B. Astor, A. Djamali.
University of Wisconsin, Madison.
Background: Polycystic kidney disease (PKD) is the underlying renal disease in 15% of kidney transplant recipients (KTRs) in the US. Post-transplant outcomes and contributing factors…
2018 American Transplant Congress
A Substantial Fraction of Surveillance Transplant Biopsies Have Clinically Actionable Findings
A. Shammout,¹ A. Naik,² M. Samaniego,² E. Farkash.¹
¹Pathology, Michigan Medicine, Ann Arbor; ²Nephrology, Michigan Medicine, Ann Arbor.
Background: Surveillance biopsies in renal transplant recipients may detect subclinical disease that affects graft longevity. At our transplant center, most patients with stable allograft function…
2018 American Transplant Congress
Haematological Autoimmune Disorders Associated with Alemtuzumab Induction in Renal and Simultaneous Pancreas and Kidney Recipients
A. Kousios,¹ R. Charif,¹ M. Atta,² A. Luqmani,² N. Cooper,² D. Taube.¹
¹Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom; ²Department of Haematology, Imperial College NHS Trust, London, United Kingdom.
Introduction Haematological Autoimmune Disorders (HAD) have been associated with Alemtuzumab (Az); namely immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AIHA), Evans syndrome (ES) and Red Cell…
2018 American Transplant Congress
Decreased Clinical Significance of Isoagglutinin Titer with the Current Desensitization Protocol in ABO-Incompatible Kidney Transplantation
C. Baek, H. Kim, W. Yang, D. Han, S-.K. Park.
Department of Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea; Department of Surgery, Asan Medical Center, Seoul, Republic of Korea.
ABO-incompatible (ABOi) kidney transplantation (KT) has become a routine procedure with graft survival rates comparable to those of ABO-compatible KT. However, the clinical significance of…
2018 American Transplant Congress
The Clinical Significance of Pretransplant C1q Assay Status in Positive Crossmatch Kidney Transplantation
J. Lee,¹ D. Kim,¹ B. Park,² S. Song,³ J. Lee,⁴ Y. Jung,¹ J. Lee,¹ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Laboratory Medicine, Asan MEdical Center, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Patients with a pretransplant donor-specific antibodies (DSA) are at higher risk for antibody-mediated rejection (AMR). However, not all DSA have the same pathogenetic potential.…
2018 American Transplant Congress
Delayed Graft Function in Live Donor HLA-Incompatible Kidney Transplant Recipients: A Multicenter Study
J. Motter,¹ A. Massie,¹ J. Garonzik Wang,¹ K. Jackson,¹ X. Luo,¹ A. Muzaale,¹ B. Orandi,² D. Segev.¹
¹JHU, Baltimore; ²UCSF, San Francisco.
Background: Many patients with a willing, but incompatible live donor choose to undergo incompatible live donor kidney transplantation (ILDKT) facilitated by desensitization procedures to eliminate…
2018 American Transplant Congress
Efficacy of IVIG + Rituximab Desensitization Therapy on HLA Antibodies is Independent of HLA Loci
X. Zhang,¹ S. Jordan.²
¹HLA and Immunogenetics Laboratory, Comprehensive Transplant Center/ Cedars-Sinai Health Systems, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Aim: Desensitization with the intravenous immunoglobulin (IVIG) and Rituximab therapy is commonly used to promote transplant of highly sensitized patients. It is suggested that HLA-DQ…
2018 American Transplant Congress
Mid-Term Outcome of Donor Specific Antibody Positive Deceased Donor Kidney Transplantation with Peri-Transplant Desensitization
K. Osickova,¹ P. Hruba,² J. Slatinska,¹ A. Slavcev,² J. Fronek,² E. Honsova,² O. Viklicky.¹
¹Dept. of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ²Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Donor specific HLA-antibodies (DSA) remain a large barrier to successful kidney transplantation and there is a limited knowledge about desensitization strategies in deceased donor programs.Anti…
2018 American Transplant Congress
B-Cell Depletion with Rituximab Exacerbates Anti-Donor CD4⁺ T-Cell Responses in Patients with Donor-Specific Anti-Human Leukocyte Antigen Antibodies
A. Tanaka, K. Ide, Y. Tanaka, M. Ohira, H. Tahara, S. Shimizu, H. Ohdan.
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Background: It has been reported that preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) were associated with poor graft outcomes in kidney transplant recipients. To eliminate…